Leerink Partners Cuts Hologic (NASDAQ:HOLX) Price Target to $90.00

Hologic (NASDAQ:HOLX) had its target price decreased by Leerink Partners from $95.00 to $90.00 in a report released on Tuesday morning, Benzinga reports. Leerink Partners currently has an outperform rating on the medical equipment provider’s stock.

HOLX has been the subject of a number of other reports. Royal Bank of Canada restated a sector perform rating and issued a $82.00 price objective on shares of Hologic in a report on Friday, August 16th. Needham & Company LLC reissued a buy rating and issued a $90.00 price target on shares of Hologic in a research note on Tuesday, September 17th. Evercore ISI upped their price target on shares of Hologic from $78.00 to $82.00 and gave the company an in-line rating in a research report on Tuesday, October 1st. Stephens reiterated an overweight rating and issued a $92.00 price objective on shares of Hologic in a report on Tuesday, July 30th. Finally, JPMorgan Chase & Co. increased their target price on Hologic from $91.00 to $95.00 and gave the company an overweight rating in a report on Tuesday, July 30th. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average price target of $87.50.

Hologic Stock Down 0.2 %

Shares of NASDAQ:HOLX opened at $79.92 on Tuesday. The firm has a fifty day moving average of $81.14 and a 200 day moving average of $77.55. Hologic has a 52-week low of $64.02 and a 52-week high of $84.67. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99. The firm has a market capitalization of $18.56 billion, a PE ratio of 27.18, a price-to-earnings-growth ratio of 2.89 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.93 EPS. As a group, research analysts anticipate that Hologic will post 4.09 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Christiana Stamoulis sold 9,039 shares of the company’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the completion of the transaction, the director now owns 45,472 shares in the company, valued at $3,615,024. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Hologic news, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total transaction of $294,237.36. Following the sale, the chief executive officer now directly owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Christiana Stamoulis sold 9,039 shares of the stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the transaction, the director now directly owns 45,472 shares of the company’s stock, valued at $3,615,024. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,280 shares of company stock worth $1,469,973. 1.75% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Hologic

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HOLX. Cetera Investment Advisers boosted its holdings in shares of Hologic by 188.9% during the 1st quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider’s stock valued at $1,595,000 after buying an additional 13,380 shares in the last quarter. Nordea Investment Management AB grew its holdings in Hologic by 1.3% in the first quarter. Nordea Investment Management AB now owns 1,507,743 shares of the medical equipment provider’s stock worth $116,797,000 after purchasing an additional 19,680 shares during the period. Clearbridge Investments LLC grew its holdings in Hologic by 51.4% in the first quarter. Clearbridge Investments LLC now owns 518,596 shares of the medical equipment provider’s stock worth $40,430,000 after purchasing an additional 176,006 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in shares of Hologic by 18.3% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,184,427 shares of the medical equipment provider’s stock worth $170,297,000 after purchasing an additional 338,212 shares in the last quarter. Finally, Mediolanum International Funds Ltd purchased a new stake in shares of Hologic in the 1st quarter worth approximately $1,793,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.